Agios Pharmaceuticals Inc EV / EBITDA
Cos'è EV / EBITDA di Agios Pharmaceuticals Inc?
EV / EBITDA di Agios Pharmaceuticals Inc è N/A
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su NASDAQ rispetto a Agios Pharmaceuticals Inc
Cosa fa Agios Pharmaceuticals Inc?
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Aziende con ev / ebitda simili a Agios Pharmaceuticals Inc
- Perk Labs ha EV / EBITDA di N/A
- Canterra Minerals ha EV / EBITDA di N/A
- Xortx Therapeutics Inc ha EV / EBITDA di N/A
- Comstock Metals Ltd ha EV / EBITDA di N/A
- Binovi Technologies ha EV / EBITDA di N/A
- RYU Apparel ha EV / EBITDA di N/A
- Agios Pharmaceuticals Inc ha EV / EBITDA di N/A
- Next Hydrogen Solutions ha EV / EBITDA di N/A
- Roots Sustainable Agricultural Technologies ha EV / EBITDA di N/A
- Emperor Capital ha EV / EBITDA di N/A
- Total Gabon ha EV / EBITDA di N/A
- China Uptown ha EV / EBITDA di N/A
- Argonaut Resources NL ha EV / EBITDA di N/A